Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice-Reference-Cited by-同舟云学术

Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice

Published:2022-06-16 Issue:8 Volume:27 Page:610-614
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Offin Michael¹^ORCID,Rusch Valerie W²,Rimner Andreas³^ORCID,Adusumilli Prasad S²,Zauderer Marjorie G¹

Affiliation:

1. Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College , New York, NY , USA

2. Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY , USA

3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center , New York, NY , USA

Abstract

Malignant pleural mesothelioma (MPM) is the most common form of mesothelioma and the type most often studied in prospective clinical trials.This review reports the trials that have shaped first-line treatment for patients with advanced/unresectable MPM and the real-world integration of first-line immune checkpoint inhibitors into clinical practice.

Funder

Memorial Sloan Kettering Cancer Center

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://academic.oup.com/oncolo/article-pdf/27/8/610/45293629/oyac113.pdf

Reference50 articles.

1. Integrative molecular characterization of malignant pleural mesothelioma;Hmeljak;Cancer Discov.,2018

2. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations;Bueno;Nat Genet.,2016

3. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study;Zauderer;Lancet Digit Health,2021

4. Deep learning-based classification of mesothelioma improves prediction of patient outcome;Courtiol;Nat Med.,2019

5. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol.,2003

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient characteristics, treatment patterns, and survival outcomes for patients with malignant pleural mesothelioma in Denmark between 2011 and 2018: a nationwide population-based cohort study;Acta Oncologica;2024-08-08

2. Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment;Annual Review of Pathology: Mechanisms of Disease;2024-01-24

3. Correlative analysis from a phase I clinical trial of intrapleural administration of oncolytic vaccinia virus (Olvi-vec) in patients with malignant pleural mesothelioma;Frontiers in Immunology;2023-02-16